Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

Giulio Metro; Antonio Passaro; Giuseppe Lo Russo; Laura Bonanno; Raffaele Giusti; Vanesa Gregorc; Enrica Capelletto; Olga Martelli; Fabiana L. Cecere; Diana Giannarelli; Andrea Luciani; Alessandra Bearz; Alessandro Tuzi; Vieri Scotti; Giuseppe Tonini; Domenico Galetta; Annamaria Carta; Hector Soto Parra; Alberto Rebonato; Alessandro Morabito; Rita Chiari

doi:10.2217/fon-2017-0441

Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

Giulio Metro, Antonio Passaro, Giuseppe Lo Russo, Laura Bonanno, Raffaele Giusti, Vanesa Gregorc, Enrica Capelletto, Olga Martelli, Fabiana L. Cecere, Diana Giannarelli, Andrea Luciani, Alessandra Bearz, Alessandro Tuzi, Vieri Scotti, Giuseppe Tonini, Domenico Galetta, Annamaria Carta, Hector Soto Parra, Alberto Rebonato, Alessandro MorabitoRita Chiari

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: Ceritinib was evaluated within a compassionate use program of Italian patients. Patients & methods: 70 patients with anaplastic lymphoma kinase-positive crizotinib-refractory advanced non-small-cell lung cancer received ceritinib. Results: Overall response was 40.6%, median progression-free survival was 8.2 months and median survival was 15.5 months. Dose reduction due to treatment-related adverse events occurred in 50.8% of patients starting at 750 mg/day. No significantly different progression-free survival was observed between patients who underwent any time dose reduction (n = 38) versus those who remained on the recommended dose of 750 mg/day (n = 32; p = 0.07). Conclusion: The efficacy of ceritinib compassionate use program resembled that of clinical trials. Dose reductions and adjustments did not appear to negatively affect clinical outcome.

Original language	English
Pages (from-to)	353-361
Number of pages	9
Journal	Future Oncology
Volume	14
Issue number	4
DOIs	https://doi.org/10.2217/fon-2017-0441
Publication status	Published - Feb 1 2018

Keywords

ALK
ceritinib
non-small-cell lung cancer

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon-2017-0441

Fingerprint Dive into the research topics of 'Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this

Metro, G., Passaro, A., Lo Russo, G., Bonanno, L., Giusti, R., Gregorc, V., Capelletto, E., Martelli, O., Cecere, F. L., Giannarelli, D., Luciani, A., Bearz, A., Tuzi, A., Scotti, V., Tonini, G., Galetta, D., Carta, A., Soto Parra, H., Rebonato, A., ... Chiari, R. (2018). Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Future Oncology, 14(4), 353-361. https://doi.org/10.2217/fon-2017-0441

Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. / Metro, Giulio; Passaro, Antonio ; Lo Russo, Giuseppe ; Bonanno, Laura; Giusti, Raffaele; Gregorc, Vanesa; Capelletto, Enrica; Martelli, Olga; Cecere, Fabiana L.; Giannarelli, Diana; Luciani, Andrea; Bearz, Alessandra; Tuzi, Alessandro; Scotti, Vieri; Tonini, Giuseppe; Galetta, Domenico; Carta, Annamaria; Soto Parra, Hector; Rebonato, Alberto; Morabito, Alessandro; Chiari, Rita.

In: Future Oncology, Vol. 14, No. 4, 01.02.2018, p. 353-361.

Research output: Contribution to journal › Article › peer-review

Metro, G, Passaro, A , Lo Russo, G , Bonanno, L, Giusti, R, Gregorc, V, Capelletto, E, Martelli, O, Cecere, FL, Giannarelli, D, Luciani, A, Bearz, A, Tuzi, A, Scotti, V, Tonini, G, Galetta, D, Carta, A, Soto Parra, H, Rebonato, A, Morabito, A & Chiari, R 2018, 'Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer', Future Oncology, vol. 14, no. 4, pp. 353-361. https://doi.org/10.2217/fon-2017-0441

Metro, Giulio ; Passaro, Antonio ; Lo Russo, Giuseppe ; Bonanno, Laura ; Giusti, Raffaele ; Gregorc, Vanesa ; Capelletto, Enrica ; Martelli, Olga ; Cecere, Fabiana L. ; Giannarelli, Diana ; Luciani, Andrea ; Bearz, Alessandra ; Tuzi, Alessandro ; Scotti, Vieri ; Tonini, Giuseppe ; Galetta, Domenico ; Carta, Annamaria ; Soto Parra, Hector ; Rebonato, Alberto ; Morabito, Alessandro ; Chiari, Rita. / Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. In: Future Oncology. 2018 ; Vol. 14, No. 4. pp. 353-361.

@article{68ceae4c8923457c8a120136441fff63,

title = "Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer",

abstract = "Aim: Ceritinib was evaluated within a compassionate use program of Italian patients. Patients & methods: 70 patients with anaplastic lymphoma kinase-positive crizotinib-refractory advanced non-small-cell lung cancer received ceritinib. Results: Overall response was 40.6%, median progression-free survival was 8.2 months and median survival was 15.5 months. Dose reduction due to treatment-related adverse events occurred in 50.8% of patients starting at 750 mg/day. No significantly different progression-free survival was observed between patients who underwent any time dose reduction (n = 38) versus those who remained on the recommended dose of 750 mg/day (n = 32; p = 0.07). Conclusion: The efficacy of ceritinib compassionate use program resembled that of clinical trials. Dose reductions and adjustments did not appear to negatively affect clinical outcome.",

keywords = "ALK, ceritinib, non-small-cell lung cancer",

author = "Giulio Metro and Antonio Passaro and {Lo Russo}, Giuseppe and Laura Bonanno and Raffaele Giusti and Vanesa Gregorc and Enrica Capelletto and Olga Martelli and Cecere, {Fabiana L.} and Diana Giannarelli and Andrea Luciani and Alessandra Bearz and Alessandro Tuzi and Vieri Scotti and Giuseppe Tonini and Domenico Galetta and Annamaria Carta and {Soto Parra}, Hector and Alberto Rebonato and Alessandro Morabito and Rita Chiari",

year = "2018",

month = feb,

day = "1",

doi = "10.2217/fon-2017-0441",

language = "English",

volume = "14",

pages = "353--361",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "4",

}

TY - JOUR

T1 - Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

AU - Metro, Giulio

AU - Passaro, Antonio

AU - Lo Russo, Giuseppe

AU - Bonanno, Laura

AU - Giusti, Raffaele

AU - Gregorc, Vanesa

AU - Capelletto, Enrica

AU - Martelli, Olga

AU - Cecere, Fabiana L.

AU - Giannarelli, Diana

AU - Luciani, Andrea

AU - Bearz, Alessandra

AU - Tuzi, Alessandro

AU - Scotti, Vieri

AU - Tonini, Giuseppe

AU - Galetta, Domenico

AU - Carta, Annamaria

AU - Soto Parra, Hector

AU - Rebonato, Alberto

AU - Morabito, Alessandro

AU - Chiari, Rita

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Aim: Ceritinib was evaluated within a compassionate use program of Italian patients. Patients & methods: 70 patients with anaplastic lymphoma kinase-positive crizotinib-refractory advanced non-small-cell lung cancer received ceritinib. Results: Overall response was 40.6%, median progression-free survival was 8.2 months and median survival was 15.5 months. Dose reduction due to treatment-related adverse events occurred in 50.8% of patients starting at 750 mg/day. No significantly different progression-free survival was observed between patients who underwent any time dose reduction (n = 38) versus those who remained on the recommended dose of 750 mg/day (n = 32; p = 0.07). Conclusion: The efficacy of ceritinib compassionate use program resembled that of clinical trials. Dose reductions and adjustments did not appear to negatively affect clinical outcome.

AB - Aim: Ceritinib was evaluated within a compassionate use program of Italian patients. Patients & methods: 70 patients with anaplastic lymphoma kinase-positive crizotinib-refractory advanced non-small-cell lung cancer received ceritinib. Results: Overall response was 40.6%, median progression-free survival was 8.2 months and median survival was 15.5 months. Dose reduction due to treatment-related adverse events occurred in 50.8% of patients starting at 750 mg/day. No significantly different progression-free survival was observed between patients who underwent any time dose reduction (n = 38) versus those who remained on the recommended dose of 750 mg/day (n = 32; p = 0.07). Conclusion: The efficacy of ceritinib compassionate use program resembled that of clinical trials. Dose reductions and adjustments did not appear to negatively affect clinical outcome.

KW - ALK

KW - ceritinib

KW - non-small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85041354775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041354775&partnerID=8YFLogxK

U2 - 10.2217/fon-2017-0441

DO - 10.2217/fon-2017-0441

M3 - Article

AN - SCOPUS:85041354775

VL - 14

SP - 353

EP - 361

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 4

ER -